FreshPatents.com Logo

new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)


Similar
Filing Names

Merck Sharp x26 Dohme Corp
Merck Sharp x26 Dohme Corporation
Merck Sharp x26 Dohme Corp And Northwestern University
Merck Sharp x26 Dohme Corp_20131212

Popular
Companies


Web
Adobe patents
Akamai patents
Amazon patents
Apple patents
Ebay patents
Facebook patents
Google patents
IBM patents
Linkedin patents
Microsoft patents
Oracle patents
Red Hat patents
Yahoo patents

Food/Health
Adidas
Nike patents
Pfizer patents
Monsanto patents
Medtronic patents
Kraft patents

Transportation
Boeing patents
Tesla Motors patents

Telecom
Qualcomm patents
Motorola patents
Nokia patents
RIMM patents

Industrial/Electronics
AMD
Applied Materials
Seagate patents
General Electric
Caterpillar patents
Samsung
Wal-mart patents

Ticker Symbols

Merck Sharp & Dohme Corp patents


      
Recent patent applications related to Merck Sharp & Dohme Corp. Merck Sharp & Dohme Corp is listed as an Agent/Assignee. Note: Merck Sharp & Dohme Corp may have other listings under different names/spellings. We're not affiliated with Merck Sharp & Dohme Corp, we're just tracking patents.

ARCHIVE: New 2014 2013 2012 2011 2010 2009 | Company Directory "M" | Merck Sharp & Dohme Corp-related inventors



Search recent Press Releases: Merck Sharp & Dohme Corp-related press releases
Count Application # Date Merck Sharp & Dohme Corp patents (updated weekly) - BOOKMARK this page
12012025303210/04/12Novel cationic lipids with short lipid chains for oligonucleotide delivery
22012020281908/09/12Combination therapy using a beta 3 adrenergic receptor agonists and an antimuscarinic agent
32014022562708/14/14 new patent  Device for calibrating and verifying the integrity of resistivity-based sensing probes
42014022722308/14/14 new patent  Pegylated interleukin-10
52014022725008/14/14 new patent  Stable formulations of antibodies to tslp
62014022729008/14/14 new patent  Method for increasing n-glycosylation site occupancy on therapeutic glycoproteins produced in pichia pastoris
72014022729208/14/14 new patent  Anti-mcam antibodies and associated methods of use
82014022002708/07/141d05 pcsk9 antagonists
92014022138308/07/14Cetp inhibitors
102014021241207/31/14Use of il-33 antagonists to treat fibrotic disease
112014020656307/24/14Biomarkers for psoriasis
122014020664007/24/142'-azido substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
132014020664107/24/14Remedy
142014020666507/24/14Selective glycosidase inhibitors and uses thereof
152014020667507/24/14Iminothiadiazine dioxide compounds as bace inhibitors, compositions, and their use
162014020671507/24/14Preparation and use of compounds as protease inhibitors
172014020018007/17/14Method for producing proteins in pichia pastoris that lack detectable cross binding activity to antibodies against host cell antigens
182014020021307/17/142-spiro-substituted iminothiazines and their mono-and dioxides as bace inhibitors, compositions and their use
192014017015406/19/14Engineered anti-il-23r antibodies
202014017065806/19/14Mammalian cytokines; related reagents
212014017143706/19/14Oxazole derivatives useful as inhibitors of faah
222014017145606/19/14Fused tricyclic compounds as mtor inhibitors
232014017148006/19/14Crystalline polymorphic forms of an antidiabetic compound
242014016177006/12/142'-cyano substituted nucleoside derivatives and methods of use thereof useful for the treatment of viral diseases
252014016179806/12/14Anti-pcsk9 and methods for treating lipid and cholesterol disorders
262014014744205/29/14Use of il-23 antagonists for treatment of infection
272014014746105/29/14Polypeptides for inducing a protective immune response against staphylococcus aureus
282014014095405/22/14Methods of modulating cytokine activity; related reagents
292014014101205/22/14Engineered anti-tslp antibody
302014014144405/22/14Isolated mammalian monocyte cell genes; related reagents
312014014144505/22/14Isolated mammalian monocyte cell genes; related reagents
322014014211505/22/14Inhibitors of the renal outer medullary potassium channel
332014014095405/22/14Methods of modulating cytokine activity; related reagents
342014014101205/22/14Engineered anti-tslp antibody
352014014144405/22/14Isolated mammalian monocyte cell genes; related reagents
362014014144505/22/14Isolated mammalian monocyte cell genes; related reagents
372014014211505/22/14Inhibitors of the renal outer medullary potassium channel
382014012836105/08/14Cyclic amide bace-1 inhibitors having a benzamide substituent
392014012836705/08/14Cycloalkyl-fused tetrahydroquinolines as crth2 receptor modulators
402014012836805/08/14Substituted cyclopropyl compounds, compositions containing such compounds, and methods of treatment
412014012836105/08/14Cyclic amide bace-1 inhibitors having a benzamide substituent
422014012836705/08/14Cycloalkyl-fused tetrahydroquinolines as crth2 receptor modulators
432014012836805/08/14Substituted cyclopropyl compounds, compositions containing such compounds, and methods of treatment
442014012003705/01/14Method for detection of amyloids beta oligomers in a fluid sample and uses thereof
452014012003705/01/14Method for detection of amyloids beta oligomers in a fluid sample and uses thereof
462014011291904/24/14Interleukin-10 antibodies
472014011392004/24/14Tricyclic heterocycles useful as dipeptidyl peptidase-iv inhibitors
482014011291904/24/14Interleukin-10 antibodies
492014011392004/24/14Tricyclic heterocycles useful as dipeptidyl peptidase-iv inhibitors
502014010588704/17/14Methods for modulating il-33 activity
512014010641304/17/14Immobilized transaminases and process for making and using immobilized transaminase
522014010734604/17/14Process for preparing chiral dipeptidyl peptidase-iv inhibitors
532014010588704/17/14Methods for modulating il-33 activity
542014010641304/17/14Immobilized transaminases and process for making and using immobilized transaminase
552014010734604/17/14Process for preparing chiral dipeptidyl peptidase-iv inhibitors
562014009356404/03/14Pharmaceutical compositions of combinations of dipeptidyl peptidase-4 inhibitors with simvastatin
572014009387504/03/14Mammalian cytokines; receptors; related reagents and methods
582014009356404/03/14Pharmaceutical compositions of combinations of dipeptidyl peptidase-4 inhibitors with simvastatin
592014009387504/03/14Mammalian cytokines; receptors; related reagents and methods
602014008804803/27/14Diazeniumdiolate cyclohexyl derivatives
612014008804803/27/14Diazeniumdiolate cyclohexyl derivatives
622014008088403/20/14Novel crystalline forms of a dipeptidyl peptidase-iv inhibitor
632014008088403/20/14Novel crystalline forms of a dipeptidyl peptidase-iv inhibitor
642014005789302/27/14Substituted cycloproply compounds, compositions containing such compounds and methods of treatment
652014005174002/20/14Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
662014004574602/13/14Antidiabetic tricyclic compounds
672014004582902/13/14Substituted 1,3-benzothiazol-2(3h)-ones and [1,3]thiazolo[5,4-b]pyridin-2(1h)-ones as positive allosteric modulators of mglur2
682014004583202/13/14Insulin-like growth factor-1 receptor inhibitors
692014003762702/06/14Modulation of pilr receptors to treat microbial infections
702014003894202/06/14Rorgammat inhibitors
712014003897002/06/14Bridged and fused antidiabetic compounds
722014003025501/30/14Methods of predicting cancer cell response to therapeutic agents
732014003076001/30/14Pavec
742014003125101/30/14Methods of classifying human subjects with regard to cancer prognosis
752014003134901/30/14Inhibitors of the renal outer medullary potassium channel
762014002366701/23/14Pyrrolidine-fused thiadiazine dioxide compounds as bace inhibitors, compositions, and their use
772014000518201/02/14Aryl methyl benzoquinazolinone m1 receptor positive allosteric modulators
782013034451212/26/13Cd16a reporter assay for evaluation of adcc potential of biologics
792013033137212/12/13Cyclic amine substituted oxazolidinone cetp inhibitor
802013033137212/12/13Cyclic amine substituted oxazolidinone cetp inhibitor
812013032323912/05/13Modulation of pilr receptors to treat sepsis
822013032324612/05/13Use of mdl-1 antagonists to treat spondylarthropathy
832013032325112/05/13Use of il-23 and il-17 antagonists to treat autoimmune ocular inflammatory disease
842013032448312/05/13Mammalian cell surface antigens; related reagents
852013032461012/05/13Cathepsin cysteine protease inhibitors
862013032472812/05/13Process for the preparation of an orexin receptor antagonist
872013031635411/28/13Mammalian cytokine; related reagents
882013029627811/07/13Diazeniumdiolate derivatives
892013028776310/31/13Combination therapy for treating cancer comprising an igf-1r inhibitor and an akt inhibitor
902013028021410/24/13Polycyclic heterocycle derivatives and methods of use thereof for the treatment of viral diseases
912013028147410/24/13Fused tricyclic inhibitors of mammalian target of rapamycin
922013026114010/03/13Tricyclic heterocycles useful as dipeptidyl peptidase-iv inhibitors
932013025167709/26/13Genetic markers associated with interferon-alpha response
942013024369209/19/13Fdg-pet evaluation of ewing's sarcoma sensitivity
952013023751809/12/13Novel compounds that are erk inhibitors
962013023085509/05/13Monocyte-derived nucleic acids and related compositions and methods
972013022558208/29/13Biaryl-spiroaminooxzaoline analogues as alpha 2c adrenergic receptor modulators
982013022583608/29/13Novel low molecular weight cyclic amine containing cationic lipids for oligonucleotide delivery
992013022558208/29/13Biaryl-spiroaminooxzaoline analogues as alpha 2c adrenergic receptor modulators
1002013022583608/29/13Novel low molecular weight cyclic amine containing cationic lipids for oligonucleotide delivery
1012013021657508/22/13Recombinant subunit dengue virus vaccine
1022013021769508/22/13Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
1032013021775608/22/13Rna interference mediated inhibition of gene expression using short interfering nucleic acids (sina)
1042013021776608/22/13Formulations for cathepsin k inhibitors
1052013021657508/22/13Recombinant subunit dengue virus vaccine
1062013021769508/22/13Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
1072013021775608/22/13Rna interference mediated inhibition of gene expression using short interfering nucleic acids (sina)
1082013021776608/22/13Formulations for cathepsin k inhibitors
1092013020306008/08/13Mammalian genes; related reagents
1102013020306008/08/13Mammalian genes; related reagents
1112013018927807/25/13Antagonists of pcsk9
1122013018927807/25/13Antagonists of pcsk9
1132013015794006/20/13Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
1142013015672906/20/13Mammalian receptor proteins; related reagents and methods
1152013015677106/20/13Fdf03 antibodies and uses thereof
1162013015794006/20/13Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
1172013015672906/20/13Mammalian receptor proteins; related reagents and methods
1182013015677106/20/13Fdf03 antibodies and uses thereof
1192013015036206/13/13Novel pyrazolo[1,5-a]pyrimidine derivatives as mtor inhibitors
1202013015036206/13/13Novel pyrazolo[1,5-a]pyrimidine derivatives as mtor inhibitors
1212013014385906/06/13Novel prolylcarboxypeptidase inhibitors
1222013014385906/06/13Novel prolylcarboxypeptidase inhibitors
1232013013104105/23/13Spirocyclic compounds
1242013013104205/23/13Spiroxazolidinone compounds
1252013013104105/23/13Spirocyclic compounds
1262013013104205/23/13Spiroxazolidinone compounds
1272013012200905/16/13Engineered anti-il-23p19 antibodies
1282013012320005/16/13Mammalian cell surface antigens; related reagents
1292013012323705/16/13Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents
1302013012200905/16/13Engineered anti-il-23p19 antibodies
1312013012320005/16/13Mammalian cell surface antigens; related reagents
1322013012323705/16/13Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents
1332013011522305/09/13Antagonists of pcsk9
1342013011623105/09/13Tyrosine kinase inhibitors
1352013011522305/09/13Antagonists of pcsk9
1362013011623105/09/13Tyrosine kinase inhibitors
1372013010973905/02/13Compositions and methods for short interfering nucleic acid inhibition of nav1.8
1382013009605304/18/13Posaconazole intravenous solution formulations stabilized by substituted beta-cyclodextrin
1392013007139003/21/13Method for preparing antibodies having improved properties
1402013006481703/14/13Engineered anti-il-23r antibodies
1412013005985003/07/13Aza-indole derivatives useful as modulators of faah
1422013005335202/28/13Diazeniumdiolate cyclopentyl derivatives
1432013004591402/21/13Biaryl spiroaminooxazoline analogues as alpha2c adrenergic receptor modulators
1442013004092902/14/13Novel prolylcarboxypeptidase inhibitors
1452013004093202/14/13Substituted aryl sulfone derivatives as calcium channel blockers
1462013003456102/07/13Isolated mammalian monocyte cell genes; related reagents
1472013003531202/07/13Cathepsin cysteine protease inhibiors
1482013002351501/24/13Novel spiropiperidine prolylcarboxypeptidase inhibitors
1492013001804801/17/13Oxazole derivatives useful as modulators of faah
1502013001252601/10/13Oxazole derivatives useful as modulators of faah
1512013000579701/03/13Endosomolytic poly(amidoamine) disulfide polymers for the delivery of oligonucleotides
1522013000451801/03/13Cyclic amine bace-1 inhibitors having a benzamide substituent
1532012032967912/27/12Eukaryotic cell display systems
1542012031532112/13/12Immunological methods and compositions for the treatment of alzheimer's disease
1552012031620012/13/12Pyridone derivatives
1562012027724011/01/12Substituted aminotetrahydrothiopyrans and derivatives thereof as dipeptidyl peptidase-iv inhibitors for the treatment of diabetes
1572012026477710/18/12Oxadiazole beta carboline derivatives as antidiabetic compounds
1582012023200709/13/12Method for producing proteins in pichia pastoris that lack detectable cross binding activity to antibodies against host cell antigens
1592012023208609/13/12Fused tricyclic compounds with adenosine a2a receptor antagonist activity
1602012022588609/06/12Novel pyrrolidine derived beta 3 adrenergic receptor agonists
1612012021484608/23/12Hexahydrocyclopentyl[f]indazole pyridyl ethanols and derivatives thereof as selective glucocorticoid receptor modulators
1622012021484708/23/122-[1-phenyl-5-hydroxy-4a-substituted-hexahydrocyclopenta[f]indazol-5-yl]ethyl phenyl derivatives as glucocorticoid receptor ligands
1632012020188508/09/12Pharmaceutical compositions of combinations of dipeptidyl peptidase-4 inhibitors with pioglitazone
1642012019690108/02/12Tertiary amide orexin receptor antagonists
1652012019070107/26/12Renin inhibitors
1662012017868107/12/12Bipiperidinyl compounds, compositions, containing such compounds and methods of treatment
1672012017875007/12/12Niacin receptor agonists, compositions containing such compounds and methods of treatment
1682012017239707/05/12Hexahydrocyclopenta[f]indazole 5-yl ethanols and derivatives thereof as selective glucocorticoid receptor modulators
1692012016415806/28/12Anti-addl monoclonal antibody and use thereof
1702012015743806/21/12Pyranyl aryl methyl benzoquinazolinone m1 receptor positive allosteric modulators
1712012015743206/21/12Novel pyrrolidine derived beta 3 adrenergic receptor agonists
1722012014277006/07/12Pharmaceutical compositions of hdac inhibitors and chelatable metal compounds, and metal-hdac inhibitor chelate complexes
1732012014269406/07/12Substituted 4-hydroxypyrimidine-5-carboxamides
1742012014275206/07/12Hiv protease inhibitors
1752012013601205/31/12Amino tetrahydro-pyridopyrimidine pde10 inhibitors
1762012012162405/17/12Hepatitis c virus ns3 protease inhibitors
1772012011913005/17/12Diaphragm valve with improved sealing performance and leak detection
1782012012150805/17/12Radiolabeled cgrp antagonists
1792012012158005/17/12Methods for producing high concentration lyophilized pharmaceutical formulations
1802012012289905/17/12Piperidinone carboxamide azaindane cgrp receptor antagonists
1812012012290005/17/12Piperidinone carboxamide azaindane cgrp receptor antagonists
1822012012291105/17/12Piperidinone carboxamide azaindane cgrp receptor antagonists
1832012011589405/10/12Imidazole derivatives useful as modulators of faah and as faah imaging agents
1842012011592105/10/12Fluoro substituted cycloalkanoindoles, compositions containing such compounds and methods of treatment
1852012010860005/03/12Substituted 4-hydroxypyrimidine-5-carboxamides
1862012009500104/19/12Substituted-1,3,8-triazaspiro[4.5]decane-2,4-diones
1872012009505504/19/12Hexahydrocyclopentyl[f]indazole 5-hydroxymethyl ethanols and derivatives thereof as selective glucocorticoid receptor modulators
1882012008348304/05/12Inhibitors of hepatitis c virus replication
1892012008267904/05/12Antagonists of pcsk9
1902012008268004/05/12Antagonists of pcsk9
1912012007679903/29/12Antagonists of pcsk9
1922012007796403/29/12Antagonists of pcsk9
1932012005318103/01/12Pyrrolidine-derived beta 3 adrenergic receptor agonists
1942012004097802/16/12Heterocyclic fused cinnoline m1 receptor positive allosteric modulators
1952012003460802/09/12Microrna as a biomarker of pancreatic islet beta-cell engagement
1962012003521402/09/12Renin inhibitors
1972012003524702/09/12Rna interference mediated inhibition of signal transducer and activator of transcription 6 (stat6) gene expression using short interfering nucleic acid (sina)
1982012002894002/02/12Functionally selective azanitrile alpha-2c adrenoreceptor agonists
1992012002905402/02/12Rna interference mediated inhibition of gata binding protein 3 (gata3) gene expression using short intefering nucleic acid (sina)
2002012002214301/26/12Rna interference mediated inhibition of the thymic stromal lymphopoietin (tslp) gene expression using short interfering nucliec acid (sina)
2012012002107401/26/12P2x3, receptor antagonists for treatment of pain
2022012002194801/26/12Surface display of whole antibodies in eukaryotes
2032012002214201/26/12Rna interference mediated inhibition of signal transducer and activator of transcription 1 (stat1) gene expression using short interfering nucleic acid (sina)
2042012001601001/19/12Rna interference mediated inhibition of btb and cnc homology 1, basic leucine zipper transcription factor 1 (bach1) gene expression using short interfering nucleic acid (sina)
2052012001601101/19/12Rna interference mediated inhibition of connective tissue growth factor (ctgf) gene expression using short interfering nucleic acid (sina)
2062012000958001/12/12Methods for quantitating small rna molecules
2072012001019301/12/12Cgrp receptor antagonists
2082012001027201/12/12Rna interference mediated inhibition of apoptosis signal-regulating kinase 1 (ask1) gene expression using short interfering nucleic acid (sina)
2092012000428101/05/12Rna interference mediated inhibition of the nerve growth factor beta chain (ngfb) gene expression using short interfering nucleic acid (sina)
2102012000428201/05/12Rna interference mediated inhibition of the intercellular adhesion molecule 1 (icam-1) gene expression using short interfering nucleic acid (sina)
2112012000428001/05/12Rna interference mediated inhibition of the high affinity 1 ge receptor alpha chain (fc epsilon r1 alpha) gene expression using short interfering nucleic acid (sina)
2122011031291112/22/11Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
2132011030107912/08/11Neuromedin u receptor agonists and uses thereof
2142011029469612/01/11Methods for characterizing agonists and partial agonists of target molecules
2152011029473512/01/11Mechanism of neuromedin u action and uses thereof
2162011029477712/01/11Beta-lactamase inhibitors
2172011026353310/27/11Novel cyclic benzimidazole derivatives useful as anti-diabetic agents
2182011025059110/13/11Method of designing sirnas for gene silencing
2192011025120710/13/11Biaryl-spiroaminooxazoline analogues as alpha 2c adrenergic receptor modulators
2202011024051110/06/11Packaging for oxygen-sensitive pharmaceutical products
2212011023763409/29/11Novel crystalline forms of an inhibitor of 11-beta-hydroxysteroid dehydrogenase type 1
2222011022950809/22/11Polypeptides for inducing a protective immune response against staphylococcus aureus
2232011023049809/22/11Biaryl carboxamides
2242011023052609/22/11Thiazolyl mglur5 antagonists and methods for their use
2252011022419309/15/11Inhibitors of diacylglycerol acyltransferase
2262011022413409/15/11Macrocyclic quinoxaline compounds as hcv ns3 protease inhibitors
2272011022419509/15/11Heterocyclic compounds as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
2282011021817409/08/11Novel cyclic benzimidazole derivatives useful as anti-diabetic agents
2292011021820209/08/11Soluble guanylate cyclase activators
2302011020773708/25/11Substituted bicyclic amines for the treatment of diabetes
2312011020794208/25/11Intermediate compounds for the preparation of trans-5-chloro-2-methyl-2,3,3a,12b-tetrahydro-1h-dibenz[2,3:6,7]-oxepino[4,5-c]pyrrole
2322011020162108/18/11Angiotensin ii receptor antagonists
2332011019595708/11/11Substituted diazepan orexin receptor antagonists
2342011019030808/04/11Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents
2352011019034608/04/11Diphenyl substituted alkanes as flap inhibitors
2362011017805907/21/111,3-oxazolidin -2-one derivatives useful as cetp inhibitors
2372011017811707/21/11Oxazolobenzimidazole derivatives
2382011017881907/21/11Devices and methods for determining a patient's propensity to adhere to a medication prescription
2392011017220507/14/11Monocyclic amide cgrp receptor antagonists
2402011015230406/23/11Spiroazaindoles
2412011013676906/09/11Method of treating men with testosterone supplement and 5alpha-reductase inhibitor
2422011012466105/26/11Oxazolobenzimidazole derivatives
2432011011833705/19/11Method of using compositions comprising mir-192 and/or mir-215 for the treatment of cancer
2442011011197605/12/11Microrna biomarkers of tissue injury
2452011011206405/12/11Pyridyl amide t-type calcium channel antagonists
2462011011207705/12/11Quinolizidinone m1 receptor positive allosteric modulators
2472011007672103/31/11Efficient production of heterologous proteins using mannosyl transferase inhibitors
2482011006566903/17/11Oxazolobenzimidazole derivatives
2492011006577803/17/11Rna interference mediated inhibition of muscarinic colinergic receptor gene expression using short interfering nucleic acid (sina)


ARCHIVE: New 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Merck Sharp & Dohme Corp in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Merck Sharp & Dohme Corp with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###

     SHARE
  
         


FreshNews promo